|
Market Closed -
NYSE
16:00:02 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 47.03 USD | -0.32% |
|
-4.49% | -4.10% |
| 10-02 | Major drugmakers turn to China for licensing deals | RE |
| 10-01 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 1,328.83 | +16.27% | 29 | ||||||
| 279.27 | +9.08% | 22 | ||||||
| 278.86 | +6.1% | 28 | ||||||
| 155.76 | +7.94% | 25 | ||||||
| 375.34 | +8.57% | 19 | ||||||
| 151.68 | +8.12% | 22 | ||||||
| 210.47 | +34.02% | 23 | ||||||
| 390.94 | -3% | 29 | ||||||
| 158.65 | +9.61% | 26 | ||||||
| 307.56 | +23.64% | 23 | ||||||
| 28.91 | +4.01% | 26 | ||||||
| 571.39 | +13.21% | 28 | ||||||
| 66.71 | +9.09% | 24 | ||||||
| 979.36 | +8.54% | 14 | ||||||
| 94.06 | +32.83% | 24 | ||||||
| 21.75 | +22.21% | 21 | ||||||
| 120.67 | -36.49% | 18 | ||||||
| 853.19 | +16.05% | 26 | ||||||
| 154.21 | +12.65% | 14 | ||||||
| Average | 343.56 | +10.66% | 23 | ||||||
| Weighted average by Cap. | 496.21 | +11.49% | 25 |
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
- Sector GSK plc
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
